Another anti-interleukin-5 monoclonal antibody drug, benralizumab (Fasenra), has been recommended for PBS listing for the treatment of uncontrolled severe eosinophilic asthma. At its March 2018 meeting the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the Section 100 (Highly Specialised Drug Program) Authority required (in writing) listing of AstraZeneca’s subcutaneous formulation of benralizumab as an alternative to ...
PBS listings approved for novel asthma and IPF treatments
By Michael Woodhead
25 Apr 2018